Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Chronic intestinal pseudo-obstruction Indication Strategy Report 2026: 5-HT4 receptor, Trials and Deals
23 July 2026
2026 Chronic intestinal pseudo-obstruction strategy: epidemiology, 5-HT4 receptor biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Bile acid diarrhea Indication Strategy Report 2026: FXR, Trials and Deals
23 July 2026
2026 Bile acid diarrhea strategy: epidemiology, FXR biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Gastroparesis Indication Strategy Report 2026: Ghrelin receptor, Trials and Deals
23 July 2026
2026 Gastroparesis strategy: epidemiology, Ghrelin receptor biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Cyclic vomiting syndrome Indication Strategy Report 2026: NK1 receptor, Trials and Deals
23 July 2026
2026 Cyclic vomiting syndrome strategy: epidemiology, NK1 receptor biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Functional dyspepsia Indication Strategy Report 2026: 5-HT4 receptor, Trials and Deals
23 July 2026
2026 Functional dyspepsia strategy: epidemiology, 5-HT4 receptor biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Porphyria cutanea tarda Indication Strategy Report 2026: UROD, Trials and Deals
23 July 2026
2026 Porphyria cutanea tarda strategy: epidemiology, UROD biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Grover disease Indication Strategy Report 2026: TRPV3, Trials and Deals
23 July 2026
2026 Grover disease strategy: epidemiology, TRPV3 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Wells syndrome Indication Strategy Report 2026: IL-5, Trials and Deals
23 July 2026
2026 Wells syndrome strategy: epidemiology, IL-5 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Eosinophilic fasciitis Indication Strategy Report 2026: IL-5, Trials and Deals
23 July 2026
2026 Eosinophilic fasciitis strategy: epidemiology, IL-5 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Morphea Indication Strategy Report 2026: TGF-beta, Trials and Deals
23 July 2026
2026 Morphea strategy: epidemiology, TGF-beta biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Discoid lupus erythematosus Indication Strategy Report 2026: TYK2, Trials and Deals
23 July 2026
2026 Discoid lupus erythematosus strategy: epidemiology, TYK2 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Cutaneous lupus erythematosus Indication Strategy Report 2026: IFNAR1, Trials and Deals
23 July 2026
2026 Cutaneous lupus erythematosus strategy: epidemiology, IFNAR1 biology, clinical competition, recent deals, unmet need and market attractiveness.